Mannkind (MNKD) Non-Current Deffered Revenue (2017 - 2026)
Mannkind (MNKD) reported Non-Current Deffered Revenue of $38.9 million for Q1 2026, down 17.85% year-over-year from $47.4 million in Q1 2025, and down 2.68% quarter-over-quarter from $40.0 million in Q4 2025.
Mannkind (MNKD) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Mannkind (MNKD) has 10 years of Non-Current Deffered Revenue data on file, last reported at $38.9 million in Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $38.9 million, down 17.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.9 million (down 17.85% YoY), and the FY2025 annual result was $40.0 million, down 21.86% from the prior year.
- Non-Current Deffered Revenue eased to $38.9 million in Q1 2026 per MNKD's latest filing, from $40.0 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $69.8 million in Q4 2023 and troughed at $1.2 million in Q1 2023.
- A 5-year average of $46.8 million and a median of $47.4 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deffered Revenue plunged 95.41% in 2023, then jumped 5545.08% in 2024.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $37.7 million in 2022, then jumped by 85.21% to $69.8 million in 2023, then dropped by 26.7% to $51.2 million in 2024, then fell by 21.86% to $40.0 million in 2025, then dropped by 2.68% to $38.9 million in 2026.
- Business Quant data shows MNKD's Non-Current Deffered Revenue at $38.9 million in Q1 2026, $40.0 million in Q4 2025, and $48.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | 38.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.91 Mn |
| Dec 31, 2025 | 39.98 Mn |
| Sep 30, 2025 | 48.19 Mn |
| Jun 30, 2025 | 45.47 Mn |
| Mar 31, 2025 | 47.36 Mn |
| Dec 31, 2024 | 51.16 Mn |
| Sep 30, 2024 | 65.15 Mn |
| Jun 30, 2024 | 66.12 Mn |
| Mar 31, 2024 | 67.74 Mn |
| Dec 31, 2023 | 69.79 Mn |
| Sep 30, 2023 | 69.47 Mn |
| Jun 30, 2023 | 60.25 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 37.68 Mn |
| Sep 30, 2022 | 32.00 Mn |
| Jun 30, 2022 | 29.76 Mn |
| Mar 31, 2022 | 26.12 Mn |
| Dec 31, 2021 | 19.54 Mn |
| Sep 30, 2021 | 1.55 Mn |
| Jun 30, 2021 | 1.59 Mn |